CD274 and cancer: A recent study showed that a secreted PDL1 splicing variant resisted PDL1 antibody treatment and that this decoying function of PDL1 variants may be one of the reasons for cancers being resistant to anti-PDL1 therapy (Sagawa et al. 2022).